Jato J G, Lake L M, Grunden E E, Johnson B M
J Pharm Sci. 1975 Jun;64(6):943-6. doi: 10.1002/jps.2600640609.
The addition of deoxyuridine (UDR) to fluorouracil (FU) or floxuridine (5-fluoro-2' deoxyuridine) (FUDR) produced a substantial increase in their toxicity in BDF1 mice. Antitumor assays using sarcoma 180 tumor-bearing mice showed a concomitant increase in tumor growth inhibition for the nucleoside-drug combination over identical doses of the single drug. However, no significant increase in antitumor activity with the combination treatment was demonstrated when equitoxic doses were given. Additional support for the therapeutic equality of the single and combination drug regimens was the similarity of the therapeutic indexes for each treatment regimen involving either fluorouracil or floxuridine. The results suggested that any therapeutic benefit achieved with the combination therapy could be duplicated with either fluorouracil or floxuridine at a higher dose.
在氟尿嘧啶(FU)或氟尿苷(5-氟-2'-脱氧尿苷)(FUDR)中添加脱氧尿苷(UDR),会使它们对BDF1小鼠的毒性大幅增加。使用荷肉瘤180肿瘤小鼠进行的抗肿瘤试验表明,与相同剂量的单一药物相比,核苷-药物组合对肿瘤生长的抑制作用随之增加。然而,当给予等毒性剂量时,联合治疗并未显示出抗肿瘤活性有显著增加。单一药物和联合药物治疗方案在治疗效果上相当的额外证据是,涉及氟尿嘧啶或氟尿苷的每种治疗方案的治疗指数相似。结果表明,联合治疗所获得的任何治疗益处都可以通过更高剂量的氟尿嘧啶或氟尿苷来实现。